
Home » SIRION THERAPEUTICS ACQUIRES U.S. LICENSE TO DEVELOP NEW TREATMENT FOR EYE DISEASE
SIRION THERAPEUTICS ACQUIRES U.S. LICENSE TO DEVELOP NEW TREATMENT FOR EYE DISEASE
Sirion Therapeutics, Inc., an ophthalmic-focused pharmaceutical company, announced today that it has reached an exclusive licensing agreement with Senju Pharmaceutical Co., Ltd. of Japan for the U.S. rights to develop and market a topical ophthalmic emulsion containing the steroid compound difluprednate for the treatment of inflammatory eye diseases. Pipeline Review (http://www.pipelinereview.com/joomla/content/view/4686/118/)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
28Sep
-
28Sep
-
11Oct
-
16Oct
-
26Oct
-
08Nov